Yu-bo C. Zhou

State Key Laboratory Of Drug Research
Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 84 publications

Design, synthesis, and biological evaluation of novel furo[3,2-b]pyrrole-benzimidazole series as potential protein tyrosine phosphatase (PTPs) inhibitors.

Design, synthesis, and biological evaluation of novel furo[3,2-b]pyrrole-benzimidazole series as potential protein tyrosine phosphatase (PTPs) inhibitors.

Journal: Bioorganic chemistry

Published: April 09, 2026

Feeding Bottles With Different Venting Methods and Gastrointestinal Discomfort in Infants: A Randomized Clinical Trial.

Feeding Bottles With Different Venting Methods and Gastrointestinal Discomfort in Infants: A Randomized Clinical Trial.

Journal: JAMA network open

Published: March 26, 2026

Beyond acrylamide: a structure-guided investigation of covalent warheads in the development of CDK7 inhibitors.

Beyond acrylamide: a structure-guided investigation of covalent warheads in the development of CDK7 inhibitors.

Journal: RSC medicinal chemistry

Published: February 04, 2026

Discovery of dihydrospiro[cyclopropane-1,7'-pyrrolo[3,4-d]pyrimidine] derivatives as novel ATR inhibitors.

Discovery of dihydrospiro[cyclopropane-1,7'-pyrrolo[3,4-d]pyrimidine] derivatives as novel ATR inhibitors.

Journal: RSC medicinal chemistry

Published: December 15, 2025

Discovery of GBA-16-24 as a highly potent, selective ATR inhibitor for the treatment of FLT3-mutated acute myeloid leukemia.

Discovery of GBA-16-24 as a highly potent, selective ATR inhibitor for the treatment of FLT3-mutated acute myeloid leukemia.

Journal: RSC medicinal chemistry

Published: November 10, 2025

Discovery of a selective CDK7 PROTAC against acute leukemia with low platelet toxicity.

Discovery of a selective CDK7 PROTAC against acute leukemia with low platelet toxicity.

Journal: Leukemia

Published: September 27, 2025

Metabolic checkpoint blockade of IL4I1 by ZY-MY-111 reactivates CD8+ T cell immunity and suppresses tumor growth.

Metabolic checkpoint blockade of IL4I1 by ZY-MY-111 reactivates CD8+ T cell immunity and suppresses tumor growth.

Journal: Acta pharmacologica Sinica

Published: September 19, 2025

Discovery of novel imidazo[2,1-b][1,3,4]thiadiazole analogs as fluorescent SHP2 inhibitors.

Discovery of novel imidazo[2,1-b][1,3,4]thiadiazole analogs as fluorescent SHP2 inhibitors.

Journal: Bioorganic chemistry

Published: April 14, 2025

Novel functionalized benzimidazole-salicylic acid derivatives: synthesis, photophysical characteristics and biological applications.

Novel functionalized benzimidazole-salicylic acid derivatives: synthesis, photophysical characteristics and biological applications.

Journal: Journal of materials chemistry. B

Published: February 14, 2025

6H-Indolo-[2,3-b]-quinoxaline derivatives as promising bifunctional SHP1 inhibitors.

6H-Indolo-[2,3-b]-quinoxaline derivatives as promising bifunctional SHP1 inhibitors.

Journal: Organic & biomolecular chemistry

Published: January 02, 2025

Development of coumarin and procaine linked hybrid molecules as a novel class of SHP1 fluorescent activators.

Development of coumarin and procaine linked hybrid molecules as a novel class of SHP1 fluorescent activators.

Journal: European journal of medicinal chemistry

Published: December 30, 2024

Potent and selective LSD1 inhibitor DC551040 reveals a promising combination therapy for AML with insight into epigenetic dysregulation.

Potent and selective LSD1 inhibitor DC551040 reveals a promising combination therapy for AML with insight into epigenetic dysregulation.

Journal: Signal transduction and targeted therapy

Published: December 24, 2024

Showing 1-12 of 84

Last Updated: 09/26/2026